Nicotine products on the market and cancer risk

Czech version

Authors: A. Pánková ^1,2; K. Zvolská ¹; E. Králíková ^1,2
Authors‘ workplace: Centrum pro závislé na tabáku, III. interní klinika – klinika endokrinologie a metabolismu 1. LF UK a VFN v Praze ¹; Ústav hygieny a epidemiologie, 1. LF UK a VFN v Praze ²
Published in: Klin Onkol 2026; 39(Supplementum 1): 31-35
Category: Review
doi: https://doi.org/10.48095/ccko2026S31

Overview

Smoking is responsible for approximately 25–30% of all oncological diseases. The link with lung cancer, which is the strongest, and is therefore well known, has been demonstrated first. Unfortunately, smoking also contributes to other types of cancer, practically all kinds except endometrial cancer. However, due to the carcinogenic and other toxic effects of several thousand substances in tobacco smoke, smoking has been increasingly replaced in recent years by smoke-free forms of nicotine. Nicotine itself is not carcinogenic; on the contrary, some forms of nicotine replacement therapy are among the World Health Organization‘s essential medicines.

Keywords:

Electronic cigarettes – nicotine – oncology – snus – nicotine pouches – heated tobacco products

Sources

1. Bele T, Turk T, Križaj I. Nicotinic acetylcholine receptors in cancer: limitations and prospects. Biochim Biophys Acta Mol Basis Dis 2024; 1870 (1): 166875. doi: 10.1016/j.bbadis.2023.166875.

2. Liu Y, Petreaca M, Martins-Green M. Cell and molecular mechanisms of insulin-induced angiogenesis. J Cell Mol Med 2009; 13 (11–12): 4492–4504. doi: 10.1111/j.1582-4934.2008.00555.x.

3. CDC. Smoking and tobacco use. Health effects of vaping. [online]. Available from: https: //www.cdc.gov/tobacco/e-cigarettes/health-effects.html.

4. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Smokeless tobacco and some tobacco-specific n-nitrosamines. IARC monographs on the evaluation of carcinogenic risks to humans, No. 89. [online]. Available from: https: //www.ncbi.nlm.nih.gov/books/NBK326497/.

5. Sanner T, Grimsrud TK. Nicotine: carcinogenicity and effects on response to cancer treatment –⁠ a review. Front Oncol 2015; 5 : 196. doi: 10.3389/fonc.2015.00196.

6. Peter J, Pritz A, Hiebler M et al. Metabolomic and gut microbial biomarkers of smoking cessation treatment in long-term drug therapy: a study protocol for a randomized controlled trial. Front Psychiatry 2026; 17 : 1677235. doi: 10.3389/fpsyt.2026.1677235.

7. Fait V. WHO melanoma programme XXXVth review meeting. Klin Onkol 1994; 7 (5): 159–160.

8. Google Patents. A method for the preparation of a nicotine-containing particulate material with a crystalline cellulose (in particular MCC). [online]. Available from: https: //patents.google.com/patent/EP1803444A2/en.

9. Delnevo CD, Hrywna M, Miller Lo EJ et al. Examining market trends in smokeless tobacco sales in the united states: 2011–2019. Nicotine Tob Res 2021; 23 (8): 1420–1424. doi: 10.1093/ntr/ntaa239.

10. Patwardhan S, Fagerström K. The new nicotine pouch category: a tobacco harm reduction tool? Nicotine Tob Res 2022; 24 (4): 623–625. doi: 10.1093/ntr/ntab198.

11. Lunell E, Fagerström K, Hughes J et al. Pharmacokinetic comparison of a novel non-tobacco-based nicotine pouch (ZYN) with conventional, tobacco-based Swedish snus and American moist snuff. Nicotine Tob Res 2020; 22 (10): 1757–1763. doi: 10.1093/ntr/ntaa068.

12. Farsalinos K. Nicotine pouches: an aid in smoking cessation, or a new public health hazard? Intern Emerg Med 2026. [Ahead of Print]. doi: 10.1007/s11739-026-04278-1.

13. Hartmann-Boyce J, Tattan-Birch H, Brown J et al. Oral nicotine pouches for cessation or reduction of use of other tobacco or nicotine products. Cochrane Database Syst Rev 2025; 10 (10): CD016220. doi: 10.1002/14651858.CD016220.pub2.

14. Hartmann-Boyce J, Butler AR, Theodoulou A et al. Biomarkers of potential harm in people switching from smoking tobacco to exclusive e-cigarette use, dual use or abstinence: secondary analysis of cochrane systematic review of trials of e-cigarettes for smoking cessation. Addiction 2023; 118 (3): 539–545. doi: 10.1111/add.16063.

15. Mendelsohn C. Youth vaping rates higher in Australia than other countries 2024. [online]. Available from: https: //colinmendelsohn.com.au/youth-prevalence/.

16. Smoking in England. Top-line findings on smoking in England from the Smoking Toolkit Study. [online]. Available from: https: //smokinginengland.info/graphs/top-line-findings.

17. NHS. Vaping to quit smoking. [online]. Available from: https: //www.nhs.uk/better-health/quit-smoking/ready-to-quit-smoking/vaping-to-quit-smoking/.

18. OMNI. THR: a global transformation. [online]. Available from: https: //asmokelessworld.com/gb/en/chapters/chapter-6/a-tale-of-two-countries-new-zealand-vs-australia.

19. Lindson N, Butler AR, McRobbie H et al. Electronic cigarettes for smoking cessation. Cochrane Database Syst Rev 2025; 1 (1): CD010216. doi: 10.1002/14651858.CD010216.pub9.

20. Fialová A, Kážmér L, Kučerová J et al. Národní výzkum užívání tabáku a alkoholu v České republice 2025 [NAUTA]. Praha: Státní zdravotní ústav 2026. [online]. Dostupné z: https: //szu.gov.cz/wp-content/uploads/2026/05/NAUTA_Narodni-vyzkum-uzivani-tabaku-a-alkoholu-v-Ceske-republice-2025.pdf.

21. Travis N, Knoll M, Cadham CJ et al. Health effects of electronic cigarettes: an umbrella review and methodological considerations. Int J Environ Res Public Health 2022; 19 (15): 9054. doi: 10.3390/ijerph19159054.

22. Rumgay H, Nethan ST, Shah R et al. Global burden of oral cancer in 2022 attributable to smokeless tobacco and areca nut consumption: a population attributable fraction analysis. Lancet Oncol 2024; 25 (11): 1413–1423. doi: 10.1016/S1470-2045 (24) 00458-3.

23. Parascandola M, Nethan ST, Siddiqi K. Smokeless tobacco and oral cancer in global perspective. N Engl J Med 2026; 394 (3): 209–211. doi: 10.1056/NEJMp2500631.

24. Public Health Agency of Sweden. Use of tobacco and nicotine products. [online]. Available from: https: //www.folkhalsomyndigheten.se/the-public-health-agency-of-sweden/living-conditions-and-lifestyle/andtg/tobacco/use-of-tobacco-and-nicotine-products/.

25. Rutqvist LE, Curvall M, Hassler T et al. Swedish snus and the Gothiatek® standard. Harm Reduct J 2011; 8 : 11. doi: 10.1186/1477-7517-8-11.

26. Swedish Match. GOTHIATEK® limits for undesired components. [online]. Available from: https: //www.swedishmatch.com/Snus-and-health/GOTHIATEK/GOTHIATEK-standard/.

27. Luo J, Ye W, Zendehdel K et al. Oral use of Swedish moist snuff (snus) and risk for cancer of the mouth, lung, and pancreas in male construction workers: a retrospective cohort study. Lancet 2007; 369 (9578): 2015–2020. doi: 10.1016/S0140-6736 (07) 60678-3.

28. Araghi M, Rosaria Galanti M, Lundberg M et al. Use of moist oral snuff (snus) and pancreatic cancer: pooled analysis of nine prospective observational studies. Int J Cancer 2017; 141 (4): 687–693. doi: 10.1002/ijc.30773.

29. Ilic I, Ilic M. International patterns in incidence and mortality trends of pancreatic cancer in the last three decades: a joinpoint regression analysis. World J Gastroenterol 2022; 28 (32): 4698–4715. doi: 10.3748/wjg.v28.i32.4698.

30. Valen H, Becher R, Vist GE et al. A systematic review of cancer risk among users of smokeless tobacco (Swedish snus) exclusively, compared with no use of tobacco. Int J Cancer 2023; 153 (12): 1942–1953. doi: 10.1002/ijc.34643.

31. St Helen G, Jacob Iii PJ, Nardone N et al. IQOS: examination of Philip Morris International’s claim of reduced exposure. Tob Control 2018; 27 (Suppl 1): s30–s36. doi: 10.1136/tobaccocontrol-2018-054321.

32. Farsalinos K, Yannovits N, Sarri T et al. Carbonyl emissions from a novel tobacco heated product (IQOS): comparison with an e-cigarette and a tobacco cigarette. Addiction 2018; 113 (11): 2099–2106. doi: 10.1111/add.14365.

33. Seidenberg A, Freeman B. IQOS is not an acronym: a call to researchers and journals. Tob Control 2021; 30 (3): 356–358. doi: 10.1136/tobaccocontrol-2019-055571.

34. Hall W, Chan G. The “gateway” effect of e-cigarettes may be explained by a genetic liability to risk-taking. PLoS Med 2021; 18 (3): e1003554. doi: 10.1371/journal.pmed.1003554.

35. Mendez D, Warner KE. A magic bullet? The potential impact of e-cigarettes on the toll of cigarette smoking. Nicotine Tob Res 2021; 23 (4): 654–661. doi: 10.1093/ntr/ntaa160.

36. Sun R, Mendez D, Warner KE. Is adolescent e-cigarette use associated with subsequent smoking? A new look. Nicotine Tob Res 2022; 24 (5): 710–718. doi: 10.1093/ntr/ntab243.

37. Balfour DJ, Benowitz NL, Colby SM et al. Balancing consideration of the risks and benefits of e-cigarettes. Am J Public Health 2021; 111 (9): 1661–1672. doi: 10.2105/AJPH.2021.306416.

38. Zvolská K, Králíková E, Štěpánková L et al. Dokumentace kuřáckého statusu osob ve screeningových programech. Stručné shrnutí operativního doporučení. [online]. Dostupné z: https: //nikez.mzcr.cz/res/guideline/summary-000249-od1-tabak-sc-strucne-shrnuti-2025-12-01-14-58-14.pdf.

39. Modrá kniha ČOS. Léčba závislosti na tabáku u onkologických pacientů. [online]. Dostupné z: https: //www.linkos.cz/lekar-a-multidisciplinarni-tym/personalizovana-onkologie/modra-kniha-cos/aktualni-vydani-modre-knihy/32-47-lecba-zavislosti-na-tabaku-u-onkologickych-pacientu/.

40. Společnost pro léčbu závislosti na tabáku. [online]. Dostupné z: https: //www.slzt.cz.